| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| CARIPRAZINE (has an active metabolite)
| CARIPRAZINE | NERVOUS SYSTEM | ORAL | Cmax 20 NANOMOLAR Tmax 4.5 HOUR PPB 94 PERCENT HT 72 HOUR | DOPAMINE D2 RECEPTOR 5-HT1A RECEPTOR | GPCR 5HT2A_HUMAN ANTAGONIST P28223 DRD2_HUMAN PARTIAL AGONIST P14416 5HT1A_HUMAN PARTIAL AGONIST P08908 | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| M CARIPRAZINE (is an active metabolite)
| CARIPRAZINE | NERVOUS SYSTEM | - | Cmax 10 NANOMOLAR PPB 94 PERCENT | DOPAMINE D2 RECEPTOR 5-HT1A RECEPTOR | GPCR 5HT2A_HUMAN ANTAGONIST P28223 DRD2_HUMAN PARTIAL AGONIST P14416 5HT1A_HUMAN PARTIAL AGONIST P08908 | EMA | |||
